Rigel Pharmaceuticals Inc · Brief

Next report

5 days

Nov 5 · after closeconfirmedQ3 FY26

Earnings

Expected move

Inputs

±10.8%implied · report alone

45.7756.85

straddle ±12.8%

spot 51.31exp Nov 20ATM strike 50ATM straddle 7.75IV 79%

Oct 30 closereport share · term structure

Expected move

Inputs

Implied vs realized

8 reportsHistory

2 of 8≥ implied

avg implied: ±14.7%
avg realized: ±11.0%

Mar 4 '25±14.2%▼−8.11%×0.57

May 6 '25±12.0%▲+1.15%×0.10

Aug 5 '25±20.8%▲+22.98%×1.10

Nov 4 '25±15.3%▲+33.37%×2.18

Jan 12 '26±10.6%▼−2.15%×0.20

Q1 FY26±15.5%▼−10.27%×0.66

May 5 '26±16.4%▼−5.06%×0.31

Q2 FY26±12.9%▲+4.60%×0.36

quarterimplied−35%0+35%realized×

Q2 FY26±12.9%▲+4.60%×0.36

May '26±16.4%▼−5.06%×0.31

Q1 FY26±15.5%▼−10.27%×0.66

Jan '26±10.6%▼−2.15%×0.20

Nov '25±15.3%▲+33.37%×2.18

Aug '25±20.8%▲+22.98%×1.10

2 older reports

May '25±12.0%▲+1.15%×0.10

Mar '25±14.2%▼−8.11%×0.57

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · confirmed

—

Linked exposure

RIGL report session

No linked exposure.

Latest changes

30 daysAll changes

Oct 29impliedImplied move: ±12.2% into Nov 5 earnings (Oct 29 close).Source

Oct 29report dateEarnings date confirmed: Nov 5, after close.Source

Oct 20impliedImplied move: ±14.4% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.